Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: a meta-analysis

• Main Authors: Liang JX, Liang Y, Gao W
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-05-01
• Series: OncoTargets and Therapy
• Subjects: Sialyl Lewis X; cancer; prognosis; meta-analysis
• Online Access: https://www.dovepress.com/clinicopathological-and-prognostic-significance-of-sialyl-lewis-x-over-peer-reviewed-article-OTT

Jin-xiao Liang,1 Yong Liang,2 Wei Gao3 1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China; 2Department of Clinical Medicine, Taizhou University Medical School, Taizhou, People’s Republic of China; 3School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang, People’s Republic of China Abstract: Many studies have shown that sialyl Lewis X (sLeX) is related to cancer prognosis and clinicopathology, but failed to provide conclusive results. We conducted the present meta-analysis to identify the association between sLeX overexpression and cancer prognosis. We searched studies in PubMed and Embase databases. Relative risk or hazard ratio with 95% confidence intervals were estimated with the Mantel–Haenszel random-effect method and 29 studies were included. Our meta-analysis showed that sLeX overexpression is significantly related to lymphatic invasion, venous invasion, T stage, N stage, M stage, tumor stage, recurrence, and overall survival. In subgroup analysis, we found that cancer type and ethnicity might be two major contributing factors to the possible presence of heterogeneity among the studies. In conclusion, sLeX overexpression is associated with tumor metastasis, recurrence, and overall survival in cancer patients, it plays an important role in cancer prognosis. Keywords: sialyl Lewis X, cancer, prognosis, meta-analysis